Pixelgen Technologies secures €12.5M in Blended Funding from the EIC Accelerator
Pixelgen Technologies Secures €12.5 Million in Blended Funding from the European Innovation Council (EIC) Accelerator.
Pixelgen Technologies, a Swedish deep tech company pioneering a new era of spatial proteomics and protein interactomics, has been awarded €12.5 million in blended funding from the European Innovation Council (EIC) Accelerator under the Horizon Europe program. The highly competitive funding includes a mix of grant and equity financing to accelerate the development and commercialization of Pixelgen’s Proximity Network Assay (PNA) platform—an innovative technology that transforms how scientists study protein interactions at nanoscale resolution.
This funding marks a major milestone for Pixelgen, which launched the Pixelgen Proxiome Kit in early 2025. The EIC support will enable the company to expand the platform into cell-cell (C2C) and FFPE tissue applications—critical tools for advancing translational research in areas such as immuno-oncology, autoimmune diseases, and personalized medicine.
By eliminating the need for expensive imaging equipment and enabling powerful 3D spatial protein mapping using standard next-generation sequencing (NGS) infrastructure, Pixelgen’s kit-based platform drastically lowers the barriers to adoption. The technology is designed for rapid global scaling and is already gaining traction with leading academic centers and pharmaceutical companies.
Simon Fredriksson, CEO and Co-founder of Pixelgen Technologies, commented:
“We’re honored to receive this endorsement from the EIC Accelerator. This support will catalyze our next phase of innovation—building on the success of our initial product and unlocking new frontiers in immuno-oncology, FFPE analysis, and translational research. The EIC’s blended finance instrument is uniquely suited for visionary deep tech platforms like PNA that require both technical and commercial de-risking.
The expertise and dedication of GAEU Consulting were instrumental in securing this highly competitive funding, guiding us through the intricate application process with unparalleled professionalism. Their strategic approach and deep knowledge of the EIC Accelerator framework have been invaluable. For any life science deep tech company aiming to navigate the complexities of European funding opportunities, GAEU is an outstanding partner and highly recommended.”
Tomasz Wąsik, MBA, CEO of GAEU Consulting Horizon Europe Centre of Excellence, added:
“Pixelgen’s success demonstrates how European research leadership can translate into global market leadership when supported by the right strategy, talent, and funding. The GAEU team provided end-to-end support—scientific, strategic, and financial—to help Pixelgen build a proposal that captured the ambition of the EIC Accelerator while addressing its rigorous expectations. We are proud to support a company pushing the frontier of spatial biology.”
Pixelgen joins a select group of visionary European companies backed by the EIC Accelerator, one of the world’s most competitive funding programs for breakthrough innovations. With this new capital, Pixelgen will scale its manufacturing, expand into new markets, and deepen its partnerships with global academic and industry leaders shaping the future of precision medicine.
